View More Recent Stories
-
Medicus Pharma (MDCX) Closes $7M Notes Offering
-
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering
-
Quantum BioPharma (QNTM) Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
-
Medicus Pharma (MDCX) Announces Pricing of $7.0 Million Public Offering, 2.2M Shares at $3.10
-
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
-
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Car
-
Medicus Pharma Ltd. (MDCX) PT Raised to $27 at D. Boral Capital
-
Medicus Pharma (MDCX) Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
-
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
-
Medicus Pharma (MDCX) Provides Update on SKNJCT-003 Phase 2 Clinical Study
-
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
-
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
-
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
-
Medicus Pharma (MDCX) Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
-
Medicus Pharma (MDCX) Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BC
-
Medicus Pharma (MDCX) Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange
-
Brookline Capital Markets Starts Medicus Pharma Ltd. (MDCX) at Buy
-
Medicus Pharma (MDCX) Announces FDA Minor Use Designation for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
-
Medicus Pharma (MDCX) Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
-
Medicus Pharma (MDCX) Appoints Faisal Mehmud as Chief Medical Officer
-
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
-
Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

